Bli medlem
Bli medlem

Du är här


Medigene AG: Medigene strengthens its DC platform with patent for treatment of stem cell or bone-marrow transplanted patients

Medigene AG / Medigene strengthens its DC platform with patent for treatment
of stem cell orbone-marrow transplanted patients . Processed and transmitted
by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
Martinsried/Munich, 23 February 2016.
Medigene AG(MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology
company focusing on the development of T cell immuno-therapies for the
treatment of cancer, announces the grant of US patent 9,238,063 by the US
Patent Office (USPTO) covering semi-allogeneic anti-tumour vaccines with
HLA[1]haplo-identical antigen presenting cells (APCs). Medigene holds an
exclusive license to the patent that was issued to Helmholtz Zentrum München
(German Research Center for Environmental Health).

Prof. Dolores Schendel, CEO and CSO of Medigene
and co-inventor of this patent, explains: "This patent increases the
applicability for Medigene's DC vaccines and complements the IP portfolio for
our DC vaccines already covered by granted patents in Europe, Australia and
the US. It is highly relevant in the immunotherapy of stem cell or
bone-marrow transplanted patients, who have received their transplants from
parents, siblings or children."

For a stem cell or bone-marrow donation without an available HLA-identical
"sibling", healthy relatives of the patient are considered meanwhile as the
best potential donors. Those donors are at least HLA haplo-identical with
respect to the patient, which means that 50% of the MHC/HLA molecules of a
donor are identical to the MHC/HLA molecules of the patient.

Currently, there are limited treatment options for patients with
haematological malignancies who suffer disease relapse after a stem cell or
bone-marrow transplantation. The patent US9,238,063 claims a method of
treating a tumour disease in patients by using semi-allogeneic antigen
presenting cells of an HLA haplo-identical donor. The APCs are modified to
express and present tumour-specific antigens which are in turn recognised by
the T cells of the patient resulting in an immune reaction directed against
the patient's residual tumour cells.

About Medigene's DC vaccines:
The platform for the development of antigen-tailored DC vaccines is the most
advanced platform of the highly innovative and complementary immunotherapy
platforms of Medigene Immunotherapies. Currently, Medigene evaluates its DC
vaccines in a company-sponsored phase I/II clinical trial in acute myeloid
leukaemia (AML). Further studies utilising Medigene's DC vaccine technology
include two ongoing clinical investigator-initiated trials (IITs): a clinical
phase I/II trial for treating acute myeloid leukaemia (AML) at Ludwig
Maximilians University Hospital Grosshadern, Munich, and a clinical phase II
trial of a treatment for prostate cancer at Oslo University Hospital.
Moreover, compassionate use patients are treated with DC vaccines at the
Department of Cellular Therapy at Oslo University Hospital.

Dendritic cells (DCs) are the most potent antigen presenting cells of our
immune system. Their task is to take up, process and present antigens on
their cell surface, which enables them to activate antigen-specific T cells
for maturation and proliferation. This way T cells can recognise and
eliminate antigen-bearing tumour cells. Dendritic cells can also induce
natural killer cells (NK cells) to attack tumour cells. The team of Medigene
Immunotherapies GmbH's scientists has developed new, fast and efficient
methods for generating dendritic cells ex-vivo, which have relevant
characteristics to activate both T cells and NK cells. The DC vaccines are
developed from autologous (patient-derived) precursor cells, isolated from
the patient's blood, and can be loaded with tumour-specific antigens to treat
different types of cancer. Medigene's DC vaccines are in development for the
treatment of minimal residual disease or use in combination therapies.

Further audio-visual education about Medigene's DC-Vaccines at:

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. The company is developing
highly innovative, complementary treatment platforms to target various types
and stages of cancer with candidates in clinical and pre-clinical
development. Medigene concentrates on the development of personalized T
cell-based immunotherapies.

For more information, please

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene
is a registered trademark of Medigene AG. This trademark may be owned or
licensed in select locations only.

Contact Medigene

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01

In case you no longer wish to receive any information about Medigene, please
inform us by e-mail ( We will then delete your address
from our distribution list.
--------------------------------------- 1 The human leukocyte antigen (HLA) system is the locus of genes that encode
for proteins on the surface of cells that are responsible for regulation of
the immune system in humans. This group of genes encodes cell-surface
antigen-presenting proteins and has many other functions. The HLA genes are
the human versions of the major histocompatibility complex (MHC) genes that
are found in most vertebrates. The major histocompatibility complex (MHC)
is a set of cell surface proteins essential for acquired immune system to
recognize foreign molecules. The main function of MHC molecules is to bind
to peptide fragments derived from pathogens or tumours and display them on
the cell surface for recognition by the appropriate T-cells.

Press release English PDF


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.